Repositioning Candidate Details
| Candidate ID: | R0245 |
| Source ID: | DB00696 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Ergotamine |
| Synonyms: | (5'α)-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione; 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione; 12'-hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3',6',18-trione |
| Molecular Formula: | C33H35N5O5 |
| SMILES: | [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O |
| Structure: |
|
| DrugBank Description: | A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. |
| CAS Number: | 113-15-5 |
| Molecular Weight: | 581.6615 |
| DrugBank Indication: | For use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia". |
| DrugBank Pharmacology: | Ergotamine is a vasoconstrictor and alpha adrenoreceptor antagonist. The pharmacological properties of ergotamine are extremely complex; some of its actions are unrelated to each other, and even mutually antagonistic. The drug has partial agonist and/or antagonist activity against tryptaminergic, dopaminergic and alpha adrenergic receptors depending upon their site, and it is a highly active uterine stimulant. It causes constriction of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The pain of a migraine attack is believed to be due to greatly increased amplitude of pulsations in the cranial arteries, especially the meningeal branches of the external carotid artery. Ergotamine reduces extracranial blood flow, causes a decline in the amplitude of pulsation in the cranial arteries, and decreases hyperperfusion of the territory of the basilar artery. It does not reduce cerebral hemispheric blood flow. |
| DrugBank MoA: | Ergotamine acts on migraine by one of two proposed mechanisms: 1) activation of 5-HT<sub>1D</sub> receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache, and 2) activation of 5-HT<sub>1D</sub> receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release. |
| Targets: | 5-hydroxytryptamine receptor 1D agonist; 5-hydroxytryptamine receptor 1B agonist; 5-hydroxytryptamine receptor 2A agonist; Dopamine D2 receptor agonist; Alpha-1A adrenergic receptor partial agonist; Alpha-1B adrenergic receptor partial agonist; Alpha-1D adrenergic receptor partial agonist; Alpha-2A adrenergic receptor partial agonist; D(1) dopamine receptor agonist; 5-hydroxytryptamine receptor 1A agonist; 5-hydroxytryptamine receptor 1F agonist; 5-hydroxytryptamine receptor 2C agonist; 5-hydroxytryptamine receptor 2B; Alpha-2C adrenergic receptor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|